Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00508287 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
A Phase 1 study of Type 2 Diabetes, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 3
- Study locations
NCT00508287: Completed Phase 1 study of Type 2 Diabetes, sponsored by Bristol-Myers Squibb.
NCT00508287 is a Phase 1 study of Type 2 Diabetes that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 36 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00508287, a Phase 1 study of Type 2 Diabetes, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single doses of BMS-686117
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-686117
- DRUG Byetta
Study Locations (3)
Florida
- Elite Research Institute - Miami
- Orlando Clinical Research Center - Orlando
Tennessee
- New Orleans Center For Clinical Research - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
What the finished NCT00508287 record still lists
NCT00508287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00508287 reports a single indexed study location in Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00508287 about?
NCT00508287 is a clinical study titled "Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes". The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single doses of BMS-686117
What is the current status of trial NCT00508287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-08. Estimated completion is 2007-11.
What conditions does trial NCT00508287 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00508287?
The interventions under investigation include: Placebo (DRUG), BMS-686117 (DRUG), Byetta (DRUG).
Who is sponsoring clinical trial NCT00508287?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00508287 being conducted?
This trial has 3 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00508287's enrollment target sits among peer trials
36 243rd of 327 higher than 83 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Pioglitazone, and Ketone Production in T2D
RECRUITING · Phase 1
-
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
RECRUITING · Phase 1
-
THC Effects on Glucose in Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
RECRUITING · Phase 1
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia